Keyphrases
A1c Levels
25%
Adjusted Analysis
12%
Antagonism
12%
Antidiabetic Drugs
100%
Antihyperglycemic
12%
Baseline HbA1c
12%
Change from Baseline
12%
Clinical Trials
12%
Clinically Significant
12%
Combination Therapy
50%
Dipeptidyl peptidase-4 (DPP-4)
25%
Drug Class
25%
First-line Drugs
12%
HbA1c Levels
12%
Hemoglobin A1c (HbA1c)
37%
Hypoglycemic Activity
50%
Hypoglycemic Drugs
12%
Inverse Probability of Treatment Weighting
12%
Japan
12%
Mechanism of Action
25%
Medical Database
12%
Metformin
100%
Monotherapy
50%
Non-insulin
12%
Propensity Score Matching
12%
Real-time Database
100%
Retrospective Cohort Study
12%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
25%
Synergism
12%
Treatment Effect
12%
Type 2 Diabetes Mellitus (T2DM)
100%
Type 2 Diabetic Patients
12%
Medicine and Dentistry
Anti-Diabetic Medication
100%
Antidiabetic Activity
12%
Antidiabetic Agent
50%
Clinical Trial
12%
Combination Therapy
50%
Dipeptidyl Peptidase-4 Inhibitor
25%
Glycon
100%
Hemoglobin A1c
50%
Hyperglycemic Agent
12%
Maturity Onset Diabetes of the Young
100%
Monotherapy
50%
Patient with Type 2 Diabetes
12%
Propensity Score Matching
12%
Retrospective Cohort Study
12%
Sodium Glucose Cotransporter 2 Inhibitor
25%
Treatment Effect
12%
Pharmacology, Toxicology and Pharmaceutical Science
Anti-Diabetic Medication
100%
Antidiabetic Agent
62%
Clinical Trial
12%
Cohort Study
12%
Combination Therapy
50%
Dipeptidyl Peptidase IV Inhibitor
25%
Hemoglobin A1c
50%
Hyperglycemic Agent
12%
Metformin
100%
Monotherapy
50%
Non Insulin Dependent Diabetes Mellitus
100%
Sodium Glucose Cotransporter 2 Inhibitor
25%
Synergism
12%
Neuroscience
Anti-Diabetic Medication
100%
Diabetes Mellitus
100%
Dipeptidyl Peptidase-4 Inhibitor
25%
Hemoglobin A1c
50%
Metformin
100%
Sodium Glucose Cotransporter 2
25%